title: Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine.
abstract: Progression to AIDS in patients harboring human immunodeficiency virus type-1 (HIV-1) isolates expressing a syncytium-inducing (SI) phenotype is faster than in those in whom the virus expresses a non-SI (NSI) phenotype. Zidovudine monotherapy does not appear to alter this outcome. To examine the role of didanosine (ddI) monotherapy in phenotype expression, HIV-1 isolates from 73 patients receiving ddI for up to 72 weeks were analyzed. After 12 weeks, the number of isolates expressing an NSI phenotype was 29% higher than at the start of treatment. Patients receiving high-dose ddI (375 mg twice daily) were significantly more likely to express the NSI phenotype at 12 weeks than patients who received low-dose ddI (100 mg twice daily), even after adjustment for phenotype and CD4 cell count at baseline, suggesting that ddI may be selective against the faster-replicating virus. ddI at 375 mg twice daily significantly increases the probability of an NSI phenotype over the short term in patients with advanced HIV disease.
authors.affiliation: Department of Biotechnology, University of South Wales, Australia.
authors.forename: N N
authors.initials: NN
authors.lastname: Zheng
authors.forename: P W
authors.initials: PW
authors.lastname: McQueen
authors.forename: L
authors.initials: L
authors.lastname: Hurren
authors.forename: L A
authors.initials: LA
authors.lastname: Evans
authors.forename: M G
authors.initials: MG
authors.lastname: Law
authors.forename: S
authors.initials: S
authors.lastname: Forde
authors.forename: S
authors.initials: S
authors.lastname: Barker
authors.forename: D A
authors.initials: DA
authors.lastname: Cooper
authors.forename: S F
authors.initials: SF
authors.lastname: Delaney
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D016049:Didanosine / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D004311:Double-Blind Method; D015726:Giant Cells; D015658:HIV Infections / Q000188:drug therapy / Q000401:mortality / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D010641:Phenotype
chemical_list: D000998:Antiviral Agents; D016049:Didanosine